ephedrine hydrazine | 91010-58-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ephedrine hydrazine
• 英文别名: (1R*,2S*)-2-(1-methylhydrazino)-1-phenyl-1-propanol；N-amino-d-pseudoephedrine；1-Methyl-1-(2-hydroxy-1-methyl-2-phenyl-ethyl)-hydrazin；2-[Amino(methyl)amino]-1-phenylpropan-1-ol
• CAS: 91010-58-1
• 化学式: C₁₀H₁₆N₂O
• 分子量: 180.25
• InChiKey: UDOPVWKLUOHIID-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ephedrine hydrazine 在 吡啶 、 硫酸 作用下， 生成 2-(1,1-dimethyl-butyl)-4,5r-dimethyl-6t-phenyl-5,6-dihydro-4H-[1,3,4]oxadiazine
  参考文献：
  名称：

  5,6-Dihydro-4H-1,3,4-oxadiazines. II. Structural Requirements for Effective Hydrazido-Hydroxyl Interaction¹

  摘要：

  DOI：

  10.1021/jo01026a036

文献信息

• Inhibitors of copper-containing amine oxidases
  申请人：Biotie Therapies Corp.

  公开号：US20020173521A1

  公开（公告）日：2002-11-21

  The present invention is directed to hydrazono compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula: 1 or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R 1 to R 8 and X are as defined herein.

  本发明涉及一种作为铜含量胺氧化酶抑制剂的肼酰基化合物，这些胺氧化酶通常被称为半卡巴嗪敏感胺氧化酶（SSAO），包括人类已知的血管粘附蛋白-1（VAP-1）胺氧化酶。这些SSAO抑制剂在治疗条件和疾病方面具有治疗效用，包括但不限于许多炎症性疾病（特别是慢性炎症性疾病，如慢性关节炎、炎症性肠病和慢性皮肤皮肤病）、与碳水化合物代谢和脂肪细胞分化或功能异常以及平滑肌细胞功能以及血管疾病相关的疾病。这些化合物具有一般公式：1或其药学上可接受的溶剂、水合物或盐，其中R1至R8和X如本文所定义。
• Synthesis of 3,4,5,6‐Tetrahydro‐2<i>H</i>‐1,3,4‐oxadiazin‐2‐ones Employing a Metal Hydride and Diethyl Carbonate: An Alternative Cyclization Method over 1,1′‐Carbonyldiimidazole
  作者：David M. Casper、David Kieser、Jennifer R. Blackburn、Shawn R. Hitchcock

  DOI：10.1081/scc-120028356

  日期：2004.12.31

  Abstract A series of 3,4,5,6‐tetrahydro‐2H‐1,3,4‐oxadiazin‐2‐ones have been synthesized from valine, leucine, ephedrine, and norephedrine. The synthesis is accomplished through a process of nitrosation, reduction, and cyclization. The cyclization protocol employed involves the use of a metal hydride (LiH or NaH) and diethyl carbonate rather than 1,1′‐carbonyldiimidazole.

  摘要 从缬氨酸、亮氨酸、麻黄碱和去甲麻黄碱合成了一系列 3,4,5,6-四氢-2H-1,3,4-oxadiazin-2-ones。合成是通过亚硝化、还原和环化过程完成的。所采用的环化方案涉及使用金属氢化物（LiH 或 NaH）和碳酸二乙酯，而不是 1,1'-羰基二咪唑。
• INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES
  申请人：Biotie Therapies Corp.

  公开号：EP1313718A2

  公开（公告）日：2003-05-28
• COMPOSITIONS USEFUL ESPECIALLY FOR TREATMENT OR PREVENTION OF METABOLIC SYNDROME
  申请人：Faron Pharmaceuticals OY

  公开号：EP1708711B1

  公开（公告）日：2010-03-17
• Aminoglycoside antibiotics for use as vap-1/ssao inhibitors
  申请人：Jalkanen Sirpa

  公开号：US20070093433A1

  公开（公告）日：2007-04-26

  The present invention concerns the use of a compound comprising one or more sugar moieties, which optionally are aminosubstitutes, and possibly other moieties, wherein said compound is a molecule comprising at least two aminosubstituents, said aminosubstituents being primary, secondary or tertiary amino groups, wherein said aminosubstituents are either attached to one single sugar moiety or attached to several sugar moieties or other moieties of the molecule, or to chains connecting two moieties or to chains being substituents to the molecule, for the manufacture of a pharmaceutical preparation useful as an agent capable of influencing an amine oxidase enzyme activity, more particularly inhibiting VAP-1/SSAO activity. The preferred compounds are aminoglycoside antibiotics, e.g., streptomycin, netilmicin, geneticin, gentamicin, puromycin, tobramycin and amikacin. The preferred conditions to be treated are inflammatory diseases or conditions, diseases related to carbohydrate metabolism, diseases related to aberrations in adipocyte differentiation or function or smooth muscle cell function, and vascular diseases.